TC BioPharm Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, TC BioPharm's Common Stock Shares Outstanding is relatively stable compared to the past year. As of 03/22/2025, Capital Lease Obligations is likely to grow to about 2.1 M, while Net Tangible Assets are likely to drop (546.9 K). Key indicators impacting TC BioPharm's financial strength include:
The essential information of the day-to-day investment outlook for TC BioPharm includes many different criteria found on its balance sheet. An individual investor should monitor TC BioPharm's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in TC BioPharm.
TC BioPharm competes with ZyVersa Therapeutics, Palisade Bio, Unicycive Therapeutics, Immix Biopharma, and Revelation Biosciences. TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what TC BioPharm's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining TC BioPharm's current stock value. Our valuation model uses many indicators to compare TC BioPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TC BioPharm competition to find correlations between indicators driving TC BioPharm's intrinsic value. More Info.
TC BioPharm Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, TC BioPharm's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value TC BioPharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
TC BioPharm Holdings Systematic Risk
TC BioPharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. TC BioPharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on TC BioPharm Holdings correlated with the market. If Beta is less than 0 TC BioPharm generally moves in the opposite direction as compared to the market. If TC BioPharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one TC BioPharm Holdings is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of TC BioPharm is generally in the same direction as the market. If Beta > 1 TC BioPharm moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as TC BioPharm is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of TCBP has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if TC BioPharm's financials are consistent with your investment objective using the following steps:
Review TC BioPharm's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand TC BioPharm's liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare TC BioPharm's financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if TC BioPharm's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in TC BioPharm Stock are looking for potential investment opportunities by analyzing not only static indicators but also various TC BioPharm's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of TC BioPharm growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of TC BioPharm help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of TC BioPharm Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of TC BioPharm Holdings based on widely used predictive technical indicators. In general, we focus on analyzing TCBP Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build TC BioPharm's daily price indicators and compare them against related drivers.
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.